Lake Shore Gazette

Leading News Website

Osteoporosis Drugs Market Sales Volume, Status, Growth, Opportunities and Global Market Share to 2031|Reach US$ 18 Bn

Osteoporosis Drugs Market 2022

The global osteoporosis drugs market is valued at US$ 12.5 Bn at present, and is expected to progress at a modest CAGR of 3.8% from 2022 to 2031, to account for US$ 18 Bn by 2031.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/2983

The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.

However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market.

Company Profiles:

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co, Inc.
  • Novartis AG
  • Amgen, Inc.
  • Novo Nordisk A / S
  • Actavis plc
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Other

In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/2983

According to the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip fractures are associated with osteoporosis.

In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness about osteoporosis care are driving the growth of the osteoporosis drug market.

According to International Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from osteoporosis in 2010, and the number is expected to reach 33.9 Mn by 2030.

However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric population and changing lifestyles in the region. Osteoporotic patients have a higher risk of hip fractures, owing to a major cause of morbidity and mortality.

According to the International Osteoporosis Foundation, by 2050, approximately 1/2 of the world’s osteoporosis hip fractures would occur in women in Asia.

Market Segmentation

By Drug Type

  • Bisphosphonates
  • Parathyroid Hormone Therapy Drugs
  • Calcitonin
  • Selective Estrogen Receptors Modulators (SERMs)
  • RANK Ligand Inhibitors

Access Full Report@ https://www.persistencemarketresearch.com/checkout/2983

Key Questions Answered in This Report.

  • What will the Market growth rate in Future?
  • What are the key factors driving the global Market?
  • Who are the key manufacturers in Market space?
  • What are the opportunities and threats faced by the vendors in the global industry?
  • What are sales, revenue, and price analysis by regions of industry?

About Us: 

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *